Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.92 USD
Change Today +0.0235 / 2.61%
Volume 53.9K
ABIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

arca biopharma inc (ABIO) Key Developments

ARCA biopharma, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

ARCA biopharma, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $2,719,000 against $2,406,000 a year ago. Net loss and comprehensive loss was $2,719,000 or $0.10 per basic and diluted share against $2,405,000 or $0.11 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $5,463,000 against $4,796,000 a year ago. Net loss and comprehensive loss was $5,463,000 or $0.22 per basic and diluted share against $4,794,000 or $0.24 per basic and diluted share a year ago.

ARCA biopharma, Inc. Regains Compliance With Minimum Bid Price Rule Of The NASDAQ Capital Market

On July 15, 2015, The Nasdaq Stock Market, notified ARCA biopharma, Inc. that the company had regained compliance with the applicable minimum bid price rule of The NASDAQ Capital Market as set forth in NASDAQ Rule 5550(a)(2). Accordingly, the previous notice received by the company on February 18, 2015 is now closed. On June 22, 2015, the company’s stockholders authorized the company’s Board of Directors for a period of up to one year, to effect a reverse split of the company’s common stock. Although the company has regained compliance with the Nasdaq listing standards, the company’s Board may still elect to proceed with the reverse split if, in the Board’s judgment, it is considered to be in the best interest of the company’s stockholders.

ARCA biopharma, Inc. Proposes Amendments to the Restated Certificate of Incorporation

ARCA biopharma, Inc. proposed to approve amendments to the Company’s restated certificate of incorporation, as amended, and authorize the Board of Directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the Board of Directors, to it's annual general meeting to be held on June 04, 2015.

ARCA biopharma, Inc., Annual General Meeting, Jun 22, 2015

ARCA biopharma, Inc., Annual General Meeting, Jun 22, 2015., at 09:00 Mountain Daylight. Location: 11080 CirclePoint Road, Suite 140. Agenda: To elect the board’s nominees, Dr. Raymond L. Woosley and Mr. Dan J. Mitchell, to the board of directors to hold office until the 2018 AGM; to ratify the selection by the audit committee of the board of directors of KPMG LLP as independent registered public accounting firm of the company for its fiscal year ending December 31, 2015; to approve amendments to the company’s restated certificate of incorporation, as amended, and authorize the board of directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the board of directors; and to conduct any other business properly brought before the meeting.

ARCA biopharma, Inc. Announces Investigation of Gencaro for the Prevention of Atrial Fibrillation/Atrial Flutter by U.S. Food and Drug Administration (FDA)

ARCA biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF). Gencaro is the company's investigational, pharmacologically unique beta-blocker and mild vasodilator. According to the FDA's Fast Track Guidance document, Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure (HFREF) population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABIO:US $0.92 USD +0.0235

ABIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABIO.
View Industry Companies
 

Industry Analysis

ABIO

Industry Average

Valuation ABIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.